Evidence map›Paper›PMID 17662090›Full record

Trial reportBritish journal of clinical pharmacology2008

Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism.

Edzard Schwedhelm, Renke Maas, Ralf Freese, Donald Jung, Zoltan Lukacs, Alen Jambrecina, William Spickler, Friedrich Schulze, Rainer H Böger

4 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in British journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 214 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 7 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02352740 nacompletednot on this mapstarted 2013, after this paper: background citation

Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.

TypeinterventionalSponsorInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementRan2013Enrolled32ConditionsOverweight, Hypertriglyceridemic WaistArmsA form Arginine, B form Arginine
NCT02354794 nacompletednot on this mapstarted 2014, after this paper: background citation

Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.

TypeinterventionalSponsorInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementRan2014 to 2014Enrolled36ConditionsOverweight, Hypertriglyceridemic WaistArmsOne form of arginine, placebo
NCT02659644 phase1withdrawnnot on this mapstarted 2015, after this paper: background citation

A Phase I Dose-Ranging Study of Oral L-citrulline in Steady-State Sickle Cell

TypeinterventionalSponsorUniversity of Mississippi Medical CenterRan2015 to 2017Enrolled0ConditionsSickle Cell DiseaseArmsOral L-citrulline
NCT03649932 phase1completednot on this mapstarted 2018, after this paper: background citation

Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing

TypeinterventionalSponsorThe University of Texas Medical Branch, GalvestonRan2018 to 2021Enrolled42ConditionsBronchopulmonary Dysplasia, Bronchopulmonary Dysplasia Associated Pulmonary Hypertension, Pulmonary Hypertension, Premature BirthArmsEnteral L-citrulline
3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 7 syntheses or guidelines pooled it, 493 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. The effect of quercetin and citrulline on cycling time trial performance.Journal of the International Society of Sports Nutrition · 2024
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Edzard SchwedhelmInstitute of Experimental and Clinical Pharmacology and Toxicology, University Medical Centre Hamburg-Eppendorf, Germany. schwedhelm@uke.uni-hamburg.de
Renke Maas
Ralf Freese
Donald Jung
Zoltan Lukacs
Alen Jambrecina
William Spickler
Friedrich Schulze
Rainer H Böger
University Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DEWest Pharmaceutical Services (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsOral L-arginine supplementation has been used in several studies to improve endothelium-dependent, nitric oxide (NO)-mediated vasodilation. L-Arginine treatment is hampered by extensive presystemic elimination due to intestinal arginase activity. In contrast, L-citrulline is readily absorbed and at least in part converted to L-arginine. The aim of our study was to assess this metabolic conversion and its subsequent pharmacodynamic effects.

methodsIn a double-blind, randomized, placebo-controlled cross-over study, 20 healthy volunteers received six different dosing regimes of placebo, citrulline, and arginine. Pharmacokinetic parameters (C(max), T(max), C(min), AUC) were calculated after 1 week of oral supplementation. The ratio of plasma L-arginine over asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase (arginine/ADMA ratio), urinary cyclic guanosine monophosphate (cGMP) and nitrate excretion rates, and flow-mediated vasodilation (FMD) was measured to assess pharmacodynamic effects.

resultsL-Citrulline dose-dependently increased AUC and C(max) of plasma L-arginine concentration more effectively than L-arginine (P < 0.01). The highest dose of citrulline (3 g bid) increased the C(min) of plasma L-arginine and improved the L-arginine/ADMA ratio from 186 +/- 8 (baseline) to 278 +/- 14 [P < 0.01, 95% confidence interval (CI) 66, 121]. Moreover, urinary nitrate and cGMP were increased from 92 +/- 10 to 125 +/- 15 micromol mmol(-1) creatinine (P = 0.01, 95% CI 8, 58) and from 38 +/- 3.3 to 50 +/- 6.7 nmol mmol(-1) creatinine (P = 0.04, 95% CI 0.4, 24), respectively. No treatment improved FMD over baseline. However, pooled analysis of all FMD data revealed a correlation between the increase of arginine/ADMA ratio and improvement of FMD.

conclusionOur data show for the first time that oral L-citrulline supplementation raises plasma L-arginine concentration and augments NO-dependent signalling in a dose-dependent manner.

Indexed as

Administration, OralArginineCitrullineCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedNitric OxideNitric Oxide SynthasePlacebosVasodilationArginineCitrullineNitric OxideNitric Oxide SynthaseN,N-dimethylargininePlacebos

Identifiers

PMID17662090
PMCPMC2291275
OpenAlexW2162463567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.